Le Lézard
Classified in: Science and technology, Business

Adjusteck Further Expands Latin America Reach by Welcoming New Partners in Ecuador and Colombia


Adjusteck announces two new additions to its global loss adjusting partner network, expanding its reach in Latin America with Ecuador-based Riesgos & Peritajes Roca Ponce and Colombia-based Valuative.

LONDON, May 24, 2022 /PRNewswire-PRWeb/ -- The international loss adjusting and claims management firm, Adjusteck LLC, welcomes two new Latin America-based partners to its expanding global network. Riesgos & Peritajes Roca Ponce brings nearly 30 years of experience as an Ecuador-based loss adjusting and claims management provider. Valuative is a Colombia-based loss adjustment and fraud investigations firm with more than 20 years of experience.

The move by Adjusteck adds capacity to handle increasing demand for Adjusteck's bespoke approach to technical, complex loss adjusting for clients in the insurance and reinsurance markets.

"We are excited to welcome these two experienced, capable firms to our network so we can more effectively meet the needs of our clients and further our reach within the global insurance community," remarks David Bosley, managing partner for Adjusteck. "I have much respect for both Valuative and Roca Ponce and look forward to continuing to grow our relationship," he concludes.

Adjusteck emphasizes a technology-oriented approach to loss adjusting and claims management, serving the global insurance and reinsurance markets with services backed by industry experts. Alongside deep subject-matter expertise, Adjusteck applies cutting-edge technology solutions, including geospatial and aerial surveys, virtual claims handling, and advanced claims management software to resolve claims with greater efficiency.

The company's services include remote and field-based claims review and oversight in Casualty, Construction, Energy, Engineering, Cyber, Financial, Natural Resources, Property, and Specie.

To learn more about Adjusteck, visit adjusteck.com.

Media Contact

Michael Gaul, Adjusteck, 1 5403387151, [email protected]

 

SOURCE Adjusteck


These press releases may also interest you

at 18:05
See On-the-Go Engraving with the xTool at Woodcraft Stores
Laser engraving just got a whole lot easier, quicker and more portable thanks to the xTool F1 Portable Laser Engraver. The machine and accessories are now available at Woodcraft. As the only woodworking retailer in the U.S. to carry the F1, Woodcraft...

at 18:01
Innovate--or Lose Your Seat at the Top Table, Retailers Warned
A new report by BCG and World Retail Congress reveals that top retailers have struggled to retain their position over the past 30 years, with many being too slow to innovate in the face of fast-evolving customer needs.60% of retail innovation leaders...

at 18:00
4DDiG Data Recovery Free V10.0.4 Released: Recover Up to 2GB Data for Free
Recently, 4DDiG, a leading software company (a unit of Tenorshare), announced the release of 4DDiG Data Recovery Free V10.0.4, which enables Windows users to recover up to 2GB of data at no cost. Although the tool is already a popular name in data...

at 18:00
Easy Way to Remove Apple ID From iPhone Without Password
One of the most common questions on Reddit is, "How to remove Apple ID from iPhone without password?" We understand that this poses a challenge for many users, says Tenorshare. Therefore, we're here to introduce some simple and practical...

at 17:55
NASA to Host a Pair of Briefings for Starliner Crew Flight
NASA will host two media opportunities on Thursday, April 25, in preparation for the agency's Boeing Crew Flight Test to the International Space Station. The mission is targeting launch at 10:34 p.m. EDT on Monday, May 6, from Space Launch Complex-41...

at 17:45
Alvotech and Teva Announce U.S. FDA Approval of SELARSDItm (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

More news about Science and technology...


News published on and distributed by: